Similarly, a secondary biomarker analysis of the FAIRLANE trial assessing the efficacy of ipatasertib in combination with paclitaxel in the neoadjuvant setting in triple-negative breast cancers (TNBC) has suggested that phosphorylation levels of AKT were associated with clinical benefit even in the absence of genetic alterations of PIK3CA, AKT, or PTEN [18]. This evidence concerns the gene AKT1 and triple-negative breast carcinoma.